Solventum (SOLV)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$89.35+5.42%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · SOLV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 3.7% |
| Our one-year growth estimate | diamond | 2.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Usually moved in the opposite direction.
Price observations: 365 days
Most sensitive to the broad stock market and long-term interest rates.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 1.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 11 industry peers · Company calendar date is not available
SOLV — litigation filed
Dated 2026-06-05
Other Events. On May 10, 2024, Plaintiff Eric Gilbert (the “Plaintiff”), on behalf of a putative class of stockholders of Solventum Corporation (the “Company”), filed a Verified Class Action Complaint (the “Action”) in the Court of Chancery of the State of Delaware (the “Delaware Court”), challenging the validity of certain aspects of the advance notice and stockholder nomination provisions of the By-laws of the Company. On September 20, 2024, the Company modified the challenged provisions by…
Why it matters: Q2 MedSurg and Dental organic sales rose 8.9% and 15.2%. Those results support Solventum’s plan to focus on MedTech.
Worry ifQ3 organic sales growth is below 5% in MedSurg or below 5% in Dental Solutions.
Less concerning ifQ3 organic sales growth is at least 8.9% in MedSurg and 15.2% in Dental Solutions.
Why it matters: Solventum is weighing several ways to separate the $1.4 billion business. A clear plan would show progress on this new priority.
Supportive ifSolventum names a deal structure and target date, with the plan still aimed at completion within 12 to 18 months.
Worry ifSolventum drops the separation plan, or reports no path forward within the stated 12-to-18-month window.
Why it matters: Free cash flow was negative $273 million in Q1, then rose to $144 million in Q2. The full-year range is now $200 million to $300 million.
Supportive ifSolventum reports at least $200 million of free cash flow for full-year 2026.
Worry ifSolventum cuts its full-year free cash flow range below $200 million.
Why it matters: Q2 organic sales rose 9.5%, helped by advance orders before ERP cutovers. Q3 can show how much growth lasts after that boost.
Supportive ifQ3 organic sales growth is at least 2.5%, the low end of the raised 2026 guidance range.
Worry ifQ3 organic sales growth is below 2.0%, the low end of the prior 2026 guidance range.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$104 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $266 loss on $10,000 · 2.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,746 loss on $10,000 · 27.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.